AntipsychoticsNCT01562808
Change in Brain Metabolism and Cognitive Function by Aripiprazole
A study testing Aripiprazole in people with Antipsychotics and Cognition, run by Seoul National University Hospital at 1 site in South Korea.
Trial summary
Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task. The investigators explored the relationship between changes in brain metabolism and working memory performance. Read more about this study
- Who is it for?
- Ages 19 to 30 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Antipsychotics, Cognition, Brain Metabolism
- What is being tested?
- Aripiprazole
- Type of treatment
- Pill or oral medicine
- How many people
- 15 participants
- Where
- 1 siteSouth Korea
- Study dates
- Jan 2009to Jan 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 30 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy volunteers
- right-handed
Who cannot join
- any significant abnormality on routine lab
- any psychiatric disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Relationship Between D2 Occupancy and Change in Frontal Metabolism and Working Memory Induced by Aripiprazole
Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task.
The investigators explored the relationship between changes in brain metabolism and working memory performance.
- Being tested
- Aripiprazole
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AripiprazoleDrug
single oral administration of aripiprazole
What is being measured
The primary outcome is the main question the study is designed to answer.
Reaction time of correct response in N-back task
Measured: 48 hrs after the administration of aripiprazole
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2012 (estimated)
- Study startJan 2009
- Primary completionMay 2010
- Study completionJan 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AntipsychoticsStudies of the same condition, open and under way.
- More trials run by Seoul National University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Seoul National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jun Soo Kwon, Seoul National University Hospital
- Investigators
- Jun Soo Kwon, M.D., Ph.D., Principal investigator, Seoul National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01562808
- Sponsor's protocol ID
- A070001
- Status last verified
- Mar 2012
- First submitted
- 22 Mar 2012
- Last updated
- 26 Mar 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Mar 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Relationship Between D2 Occupancy and Change in Frontal Metabolism and Working Memory Induced by Aripiprazole
- ClinicalTrials.gov ID
- NCT01562808
- Acronym / sponsor ID
- A070001
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Seoul National University HospitalUniversity, hospital or other
- Study start
- Jan 2009
- Primary completion
- May 2010 (actual)
- Study completion
- Jan 2012 (actual)
- First posted
- 26 Mar 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task.
The investigators explored the relationship between changes in brain metabolism and working memory performance.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- Single blind (participant)
Who may qualify
- Ages
- 19 to 30 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- healthy volunteers
- right-handed
Key exclusion criteria (2 listed)
- any significant abnormality on routine lab
- any psychiatric disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Aripiprazolesingle oral administration of aripiprazole | Drug | – |
Primary outcome
Reaction time of correct response in N-back task
Time frame: 48 hrs after the administration of aripiprazole
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Mar 2012.
Related trials for Antipsychotics
Recruiting
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
Schizophrenia, Antipsychotic Induced Weight Gain
Recruiting
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
Schizophrenia Spectrum, Schizophrenia
Active, not recruiting
Effects of Antipsychotics on Brain Insulin Action in Females
Insulin Resistance, Menstrual Cycle
Not yet recruitingPhase 3
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Schizophrenia Disorder, Metabolic Syndrome
Not yet recruitingPhase 1/2
Xingqi Daozhi Decoction for Antipsychotic-Induced Constipation
Schizophrenia, Antipsychotic Drug
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jun Soo Kwon, M.D., Ph.D. principal investigator
Seoul National University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Aripiprazole in people with Antipsychotics and Cognition, run by Seoul National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Mar 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reaction time of correct response in N-back task (time frame: 48 hrs after the administration of aripiprazole). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2012; AzTrials last refreshed its copy on 30 Oct 2026.